Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 15, Issue 1, Pages 101-118Publisher
WILEY
DOI: 10.1111/ajt.13050
Keywords
alloantibody; desensitization; kidney transplantation; nephrology; plasma cells; translational research; science
Categories
Funding
- Millennium
Ask authors/readers for more resources
A prospective iterative trial of proteasome inhibitor (PI)-based therapy for reducing HLA antibody (Ab) levels was conducted in five phases differing in bortezomib dosing density and plasmapheresis timing. Phases included 1 or 2 bortezomib cycles (1.3mg/m(2)x6-8 doses), one rituximab dose and plasmapheresis. HLA Abs were measured by solid phase and flow cytometry (FCM) assays. Immunodominant Ab (iAb) was defined as highest HLA Ab level. Forty-four patients received 52 desensitization courses (7 patients enrolled in multiple phases): Phase 1 (n=20), Phase 2 (n=12), Phase 3 (n=10), Phase 4 (n=5), Phase 5 (n=5). iAb reductions were observed in 38 of 44 (86%) patients and persisted up to 10 months. In Phase 1, a 51.5% iAb reduction was observed at 28 days with bortezomib alone. iAb reductions increased with higher bortezomib dosing densities and included class I, II, and public antigens (HLA DR3, HLA DR4 and HLA DR5). FCM median channel shifts decreased in 11/11 (100%) patients by a mean of 10354 mean channel shifts (log scale). Nineteen out of 44 patients (43.2%) were transplanted with low acute rejection rates (18.8%) and de novo DSA formation (12.5%). In conclusion, PI-based desensitization consistently and durably reduces HLA Ab levels providing an alternative to intravenous immune globulin-based desensitization. A prospective, iterative trial of five proteasome inhibitor (bortezomib)-based desensitization regimens demonstrates that these regimens can provide significant reductions in HLA antibodies with substantial durability. See editorial by Budde and Lehner on page .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available